Anti‐ PF4 disorders: Pathogenesis, diagnosis and treatment
British Journal of Haematology · 2025-09 · 207 (3) · 709-722
DOI: 10.1111/bjh.20216 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2025-07. Verfasst von Megan V Preece und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Platelet Factor 4, Thrombosis, Thrombocytopenia, Autoantibodies. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council UK.
Abstract (Originalsprache)
Platelet factor 4 (PF4) is a cationic protein, able to form complexes with negatively charged molecules upon its self‐assembly into PF4 tetramers. The targeting of these PF4 complexes by immunoglobulin G (IgG) antibodies underlies anti‐PF4 disorders such as heparin‐induced thrombocytopenia (HIT) and Vaccine‐Induced Immune Thrombocytopenia and Thrombosis (VITT)/VITT‐like disorders. The formation of IgG/PF4 immune complexes facilitates uncontrolled activation of platelets, neutrophils and monocytes, via IgG‐mediated Fcγ receptor binding. This promotes the thrombocytopenia and thrombosis characteristic of anti‐PF4 disorders. HIT is predominantly triggered by heparin exposure. VITT is a recently recognised anti‐PF4 disorder, which developed following specific SARS‐CoV‐2 vaccinations. It is thought that hexon proteins, components of adenoviral vectors, may form complexes with PF4 to trigger anti‐PF4 antibody production in VITT. A novel anti‐PF4 disorder has been recognised causing platelet activation without the administration of heparin or SARS‐CoV‐2 vaccination and referred to as ‘VITT‐like disorder.’ Clinical evaluation of HIT and VITT/VITT‐like disorders is based on thrombotic events, platelet counts and D‐dimer levels. Laboratory assays such as heparin/PF4‐induced platelet activation assays can be used to distinguish between HIT and VITT. Treatment plans for HIT and VITT may differ across patient groups. In this review, we discuss the pathogenesis, diagnosis and management of anti‐PF4 disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.
- Department of Haematology, Imperial College Healthcare NHS Trust, London, UK.
ORCID-Profile: Mike Laffan, Deepa J Arachchillage
Förderung
- Medical Research Council UK
Zitieren
APA
Preece, M. V., Pathak, D. V., Laffan, M., & Arachchillage, D. J. (2025). Anti‐ PF4 disorders: Pathogenesis, diagnosis and treatment. British Journal of Haematology, 207(3), 709-722. https://doi.org/10.1111/bjh.20216
Vancouver
Preece MV, Pathak DV, Laffan M, Arachchillage DJ. Anti‐ PF4 disorders: Pathogenesis, diagnosis and treatment. British Journal of Haematology. 2025;207(3):709-722. doi:10.1111/bjh.20216
BibTeX
@article{Preece2025,
author = {Preece, Megan V and Pathak, Devi V and Laffan, Mike and Arachchillage, Deepa J},
title = {Anti‐ PF4 disorders: Pathogenesis, diagnosis and treatment},
journal = {British Journal of Haematology},
year = {2025},
volume = {207},
number = {3},
pages = {709--722},
doi = {10.1111/bjh.20216}
}
EUVIMED